EdiGene Announces Completion of Last Patient Dosing in Phase I Clinical Trial of ET-01, its Investigational Gene-editing Hematopoietic Stem Cell Therapy for Transfusion Dependent ?-thalassemia
BEIJING & WALTHAM, Mass.--(BUSINESS WIRE)--EdiGene, Inc., a global, clinical-stage company focused on translating gene-editing technologies into transformative genetic medicines for...




















